,i #aagth ,,congress #ast ,session ,h4 ,r4 #cgje ,,in ,,the ,,house ,,of ,,representatives ,june #d1 #bjba,mr4 ,griffith introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to include a safe harbor for communication of information with respect to a vaccine authorized for emergency use under such ,act that is provided or distributed to a health care provider1 and for other purposes4 #a4 ,safe harbor for communications about vaccines authorized for emergency use 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #ejb 7#ba ,u4,s4,c4 #ceb7 the following3 #ejb;,a4 ,safe harbor for communications about vaccines authorized for emergency use 7a7 ,in general ,the communication of information 7through written or oral means71 described in subsection 7b71 with respect to the use of a vaccine authorized for emergency use under section #efd provided or distributed to a covered health care entity shall not be a basis for treating such vaccine as1 or be treated as evidence that such vaccine is-- 7#a7 misbranded under subsection 7a7 or 7f7 of section #ejb2 or 7#b7 in violation of section #eje or #efd of this ,act or subsection 7a7 or 7k7 of section #cea7;a77#a7 of the ,public ,health ,service ,act1 as applicable4 7b7 ,information described ,information described in this subsection is any information relating to a use of a vaccine authorized for emergency use under section #efd within the scope of that authorization that-- 7#a7 is neither false nor misleading1 when measured objectively against the information available at the time the statement is made2 7#b7 is accompanied1 as required1 by an appropriate disclaimer1 including-- 7,a7 a statement identifying any differences between the information and any authorized labeling of the vaccine2 7,b7 a statement identifying contradictory evidence2 and 7,c7 such other information as may be required by regulation2 and 7#c7 is based on competent and reliable scientific evidence1 as described in subsection 7e74 7c7 ,coverage not excluded ,the distribution of information that otherwise meets the requirements of this section shall not fail to meet the requirements of subsection 7a7 because the manufacturer or distributor of the vaccine about which information is being distributed has-- 7#a7 knowledge that such vaccine is being used by patients or health care practitioners in a manner not described in any authorized labeling of the vaccine1 as applicable2 or 7#b7 objective or subjective intent that such vaccine be used in a manner inconsistent with any labeling1 as applicable1 of such vaccine4 7d7 ,rule of construction ,nothing in this section shall be construed-- 7#a7 to limit communication to which this section does not specifically apply2 or 7#b7 to alter or expand the authority of the ,secretary to enforce the provisions of this ,act of section #cea of the ,public ,health ,service ,act1 except with respect to the communication of information to which this section specifically applies4 7e7 ,definitions ,in this section3 7#a7 ,competent and reliable scientific evidence 7,a7 ,in general ,in this section1 the term competent and reliable scientific evidence means evidence established through scientific methods that are widely accepted by experts in the relevant field and followed pursuant to a clear and well-described protocol1 as scientifically appropriate1 regardless of whether such evidence is supported by #b adequate and well-controlled clinical studies4 7,b7 ,inclusions ,such term may include information-- 7i7 derived from clinical trials1 observational studies1 clinical studies or bench tests that describe performance1 database reviews1 registries1 patient utilization projections1 and modeling techniques1 and the data1 inputs1 and components of such information2 7ii7 about the effects of a vaccine in subgroups defined by demographic or other variables1 including groups defined by race1 sex1 risk factors1 or other variables1 such as genomic features or disease severity2 7iii7 related to the authorization for emergency use under section #efd1 as applicable2 and 7iv7 relating to the safety1 effectiveness1 or benefit of a use or treatment that is authorized for emergency use under section #efd for a vaccine1 including information regarding-- 7,i7 health outcomes1 patient or caregiver experience1 or other quality metrics2 and 7,,ii7 the comparative effectiveness of a vaccine relative to other products1 other health care interventions1 program and quality improvement interventions1 or no intervention4 7#b7 ,covered health care entity ,the term covered health care entity means a health care provider1 health care institution1 payor1 formulary committee1 or other similar entity carrying out responsibilities for making drug coverage1 reimbursement1 or usage decisions on a population basis4 4